Navigation Links
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
Date:3/12/2009

Provides first affordable protease inhibitor for patients in developing countries Complements recent WHO approval earned for the same product

PITTSBURGH, March 12 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, has received the first and only tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Lopinavir/Ritonavir Tablets, 200 mg/50 mg. Matrix's version of this product is heat-stable and affordable, making it practical for distribution and use in warm climates.

Mylan Vice Chairman and CEO Robert J. Coury said: "Mylan and Matrix are committed to our growing and high quality antiretroviral franchise. Our goal is to provide HIV treatments to patients around the world -- especially in developing countries. With Matrix's heat-stable and affordable version of Lopinavir/Ritonavir, patients in remote parts of developing nations will have access to this important life-saving drug. This is the second regulatory approval that this important product has recently earned, which further confirms our commitment to providing high-quality medicines at affordable prices."

Lopinavir/Ritonavir Tablets are the generic version of Abbott Laboratories' Kaletra(R) Tablets, the brand marketed in the U.S. and Europe, and Aluvia(R) Tablets, the brand marketed in developing countries. It is used in combination with other medications to control HIV infection and is included in the antiretroviral (ARV) class of drugs known as HIV protease inhibitors.

Last month, Matrix was awarded the first and only World Health Organization (WHO) approval for the same product. These approvals
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. CorMatrix Cardiovascular Announces First European Implants of CorMatrix(R) ECM Technology(TM)
2. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
4. Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share
5. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2009 Financial Results
6. Matrixx Initiatives Selects GolinHarris as Agency of Record for Zicam Brand
7. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
8. BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development
9. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
10. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
11. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... News) -- The holidays can be a challenge for people ... foods and drinks. "This is the season in which ... migraine," Dr. David Dodick, chair of the American Migraine Foundation, ... important to think through food and beverage choices, to help ... a professor of neurology at the Mayo Clinic in Scottsdale, ...
(Date:12/24/2014)... (HealthDay News) -- A new, injectable weight-loss drug has ... The agency on Tuesday approved Saxenda (liraglutide) for ... overweight and have at least one weight-related health condition, ... high cholesterol. Patients taking the drug, made by ... exercise regularly, the FDA noted. "Obesity is a ...
(Date:12/24/2014)... Researchers say they have used human embryonic stem cells ... While this had already been done using rodent ... types of cells -- called primordial germ cells -- ... to the team at the University of Cambridge in ... one of the earliest events during early mammalian development," ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A lab technician with ... have been exposed to the Ebola virus in an ... up to a dozen other lab workers are being ... afternoon. The possible exposure occurred Monday when CDC ... of the potentially lethal virus to another CDC lab ...
(Date:12/24/2014)... 2014 Gluten, a protein found predominately ... have an intolerance to gluten, causing side effects that ... headaches, joint pain and fatigue. For this reason, Diet ... that deliver safe and fast weight loss while teaching ... gluten allergy reaction. These gluten free diet plans combine ...
Breaking Medicine News(10 mins):Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... outstanding growth, and success in navigating troubled economy. , ... ... [Jackson Healthcare] (JH) has been named to Inc. magazine,s second annual ... most entrepreneurial private companies. Jackson Healthcare is ranked 40th on ...
... Patient Safety,Technologies, Inc. (PST) (OTC Bulletin Board: PSTX) ... equity financing in a first closing of a,private placement. ... at its SurgiCount Medical subsidiary. Investors in the first,closing ... common stock at a price of $1.25 per share ...
... SOUTH SAN FRANCISCO, Calif., Aug. 27 VaxGen,Inc. ... a financial and operational update since the filing ... Securities and Exchange Commission,on August 14, 2008., ... $59 million in cash and equivalents and,investment securities ...
... preterm birth cuts risk in half, study finds , , WEDNESDAY, ... at risk of preterm delivery, cut the rate of cerebral ... found. , "If deemed to be at high or immediate ... doctors should consider using magnesium sulfate to prevent their child ...
... COLUMBUS, Ga., Aug. 27 Aflac Incorporated,(NYSE: AFL ... at the Keefe,Bruyette & Woods 2008 Insurance Conference. President ... Incorporated, and he is,scheduled to make a presentation on ... Incorporated presentation, Mr. Cloninger will discuss the,company,s outlook for ...
... Preparedness Event to be held on September 8, 2008, ... Adult Center in Burbank will be hosting a Disaster Preparedness,Event ... City of Burbank. The focus of this event is to ... to look after yourself in an emergency.,Participants will learn how ...
Cached Medicine News:Health News:Jackson Healthcare Ranked 48th of All Health Companies on Inc. Magazine's 2008 List of 5000 Fastest Growing Private Companies 2Health News:Patient Safety Technologies Closes on $2.325 Million in Equity Financing 2Health News:VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment 2Health News:VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment 3Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 3Health News:Aflac Incorporated To Present at the Keefe, Bruyette & Woods 2008 Insurance Conference 2
(Date:12/24/2014)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... on December 24, 2014 it closed its previously ... raised approximately $2.3 million in gross proceeds from ... proceeds from the offering to fund its research ...
(Date:12/24/2014)... LONDON , December 24, 2014 ... grow at an average rate of 8.1%. The US ... Hip, knee and spine surgeries are the common orthopedic ... they have a lower penetration. Increased number of product ... composites. Non-metallic orthopedic devices have gained popularity in the ...
(Date:12/24/2014)... LifeScienceIndustryResearch.com adds 2014 ... Industry of 178 pages providing 10 company ... The 2014 Market Research Report ... professional and deep research report on Global ... report introduces Disposable Syringe basic information including ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... 500th sale of its ExacTrac® patient positioning ... physicians continued focus on adopting clinically proven systems for ... access to advanced radiation therapy for patients. ... decade ago, has been proven consistent and reliable in ...
... FRANCISCO, Jan. 16, 2012 Dicom Systems ( http://www.dcmsys.com ... pleased to announce their selection as the Vendor Neutral ... full service physician-owned teleradiology group. Dicom ... have the capacity to turn your current storage to ...
Cached Medicine Technology:Brainlab ExacTrac® System Achieves Major Sales Milestone 2ONRAD, Inc. Chooses Dicom Systems' Vendor Neutral Archive 2
... Upper extremity fixator has been designed to ... by allowing independent movement of its clamp ... goals has been to reduce complexity of ... ease of use. The Hoffmann® II Compact™ ...
Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
... System for distal radius fractures allows incremental ... and rotation. The unique wrist lock enables ... extension without losing fracture reduction. Post-op adjustments ... surgeons office. Priced competitively and sold in ...
... The Universal Mini External ... hold using smooth, thin diameter ... 2.5 mm). This hold ... frame which stabilizes fractures and ...
Medicine Products: